证券日报网讯 2月24日，海特生物在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 人数为16889户。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Hite Bio (300683) plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, effectively achieving full control [1] - This acquisition is a follow-up to a share purchase agreement signed in 2014 and aims to integrate the innovative drug research and development platform, paving the way for the commercialization of the core drug CPT (recombinant structural human tumor necrosis factor-related apoptosis-inducing ligand) [1] - The share acquisition process has taken over ten years, and this transaction marks the final stage of integration [1] Group 2 - In the past week (February 7 to 13, 2026), Hite Bio's stock price has shown a volatile downward trend, peaking at 36.03 yuan on February 10, with a single-day increase of 3.17%, but subsequently retracing to a closing price of 32.22 yuan on February 13, resulting in a cumulative decline of 3.13% over five days [2] - On February 10, the turnover rate reached 9.89%, with a trading volume of 419 million yuan, indicating active short-term trading; however, on February 12, there was a net outflow of 14.9611 million yuan from main funds, accounting for 9.75% of the total trading volume [2] - The technical analysis indicates increased volatility in the stock price, with the 20-day Bollinger Bands showing a resistance level at 35.12 yuan and a support level at 27.72 yuan [2] Group 3 - Institutional attention on Hite Bio is relatively low, with the latest sentiment being neutral; one institution predicts a net profit of 77 million yuan for 2025, representing a year-on-year increase of 283.33%, and a forecast of 339 million yuan for 2026, reflecting a year-on-year growth of 340.26%, primarily due to expectations regarding the commercialization potential of the innovative drug CPT [3] - Currently, 100% of institutional ratings are neutral, with no clear target price guidance provided [3]

Core Viewpoint - Hite Bio plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, nearly achieving full control over the company and paving the way for the commercialization of its core drug candidate CPT [2][4]. Group 1: Acquisition Details - The acquisition process began in December 2014 with a signed equity acquisition agreement involving multiple stakeholders [3]. - Hite Bio's gradual increase in stake included cash rewards and management of unexercised incentive shares to optimize Beijing Shadong's equity structure [3]. - By April 2024, Hite Bio's stake reached 75.76% through significant share acquisitions, leading to the current acquisition announcement [4]. Group 2: Strategic Importance - The primary motivation for Hite Bio's investment in Beijing Shadong is the core asset, the innovative drug CPT, which is a recombinant biologic for tumor treatment [5]. - Controlling Beijing Shadong allows Hite Bio to directly manage a valuable drug development pipeline, supporting its transition to an innovation-driven biopharmaceutical company [5]. - The acquisition will enable better resource integration and decision-making processes, preparing for CPT's clinical trials and commercialization [5]. Group 3: Future Implications - Successful approval and commercialization of CPT could significantly enhance Hite Bio's revenue and market position in the oncology sector [5]. - Full consolidation of Beijing Shadong into Hite Bio's financial statements will facilitate future planning and value maximization for the drug in global markets [5].

Policy Developments - The National Health Commission and 10 other departments jointly issued the "National Basic Drug Directory Management Measures," which revises six key areas, including legal policy basis, directory structure optimization, management mechanism improvement, emphasis on clinical value, dynamic adjustment mechanism, and monitoring and evaluation enhancement [1][2]. Drug and Device Approvals - Hengrui Medicine announced that its injection of Rukang Qutuzumab has been included in the list of breakthrough therapy varieties, marking the 10th indication for this drug, aimed at treating locally advanced or metastatic non-small cell lung cancer patients with HER2 mutations [3]. - Shanghai Pharmaceuticals received approval for the listing application of the raw material drug Tamsulosin Hydrochloride, which is used for treating benign prostatic hyperplasia, with an investment of approximately RMB 1.5 million in its development [4]. Financial Reports - WuXi Biologics expects a 46.3% year-on-year increase in net profit for the full year 2025, projecting revenues of approximately RMB 21.79 billion and an adjusted net profit of about RMB 6.59 billion [5]. - Eucare Pharmaceuticals reported a 48.21% decline in net profit for 2025, with revenues of RMB 334 million, reflecting a 7.73% increase [6]. Capital Markets - Watson Bio plans to invest RMB 450 million to establish a biological industry investment fund with a target size of RMB 1 billion, focusing on synthetic biology and related sectors [7]. - Hite Bio intends to acquire a 23.08% stake in Beijing Shadong for RMB 62.02 million, increasing its ownership to 98.84% [8]. - Duorui Pharmaceuticals announced a partial tender offer to acquire 24.30% of its shares at a price of RMB 32.07 per share [9]. Industry Events - China's first C909 "airplane hospital" successfully completed its first in-flight surgery in Laos, providing medical services to over 600 patients since its launch [10]. - Researchers revealed the key mechanism of the "weight loss miracle drug" Semaglutide, showing its significant cartilage protection effects independent of weight loss, providing new drug development targets for metabolic osteoarthritis [11]. Public Sentiment Alerts - Shuyou Shen announced that its major shareholder, Xiangtang Group, has cumulatively reduced its holdings by 4.78 million shares, accounting for 1% of the total share capital [12].

Group 1 - The core viewpoint of the article is that Hite Bio (300683.SZ) currently does not face the risk of being designated as ST (Special Treatment) [1] Group 2 - The company has communicated this information through its interactive platform [1]

证券代码：300683 证券简称：海特生物 公告编号：2026-013 武汉海特生物制药股份有限公司 关于对外投资的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 武汉海特生物制药股份有限公司（以下简称"公司"）于 2014 年 12 月 8 日与 君和企业有限公司、北京康华投资有限公司，朱冰、杨世方、崔俊生，沙炳东、 郭诚，中关村发展集团股份有限公司签署了《股权收购协议书》(以下简称"协议 书")。协议约定：自北京沙东生物技术有限公司（以下简称"北京沙东"）研发的 国家Ⅰ类新药"重组变构人肿瘤坏死因子相关凋亡诱导配体"（以下简称"CPT"） 正式上市销售后的 2 年内，公司需按照协议约定收购相关方剩余股权。 详细内容请见公司在指定信息披露媒体巨潮资讯网（www.cninfo.com.cn）上 披露的招股说明书第十一节其他重要事项之股权收购协议。 《股权收购协议书》已经公司第五届董事会第六次会议、2014 年第二次临 时股东会审议通过，此次情况无需再提交董事会和股东会审议。 二、协议签订后的后续进展情况 （一）股权激励 2015 年 1 ...

证券代码：300683 证券简称：海特生物 公告编号：2026-012 武汉海特生物制药股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会召开期间没有增加、否决或变更议案情况发生； 2、本次股东会没有涉及变更前次股东会决议； 3、本次股东会采取现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开时间 （1）现场会议召开时间：2026 年 2 月 5 日（星期四）14:30。 （2）网络投票时间：2026 年 2 月 5 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 2 月 5 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过互联网投 票系统进行网络投票的具体时间为：2026 年 2 月 5 日 9:15 至 15:00 期间的任意 时间。 （二）现场会议召开地点 湖北省武汉市经济技术开发区海特科技园会议室。 （三）会议召集人：公司董事会 （四）会议召开方式：本次会议采取现场投票和网络投票相 ...

北京高文（武汉）律师事务所 关于武汉海特生物制药股份有限公司 2026 年第一次临时股东会的 法律意见书 二〇二六年二月 北京高文（武汉）律师事务所 关于武汉海特生物制药股份有限公司 2026 年第一次临时股东会的 法律意见书 致：武汉海特生物制药股份有限公司 北京高文（武汉）律师事务所（以下简称"本所"）接受武汉海特生物制药 股份有限公司（以下简称"公司"）委托，指派本所律师对公司 2026 年第一次 临时股东会（以下简称"本次股东会"）的合法性进行见证并出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《证券法》、中国证券监督管理委员会（以下简称"中国证 ...

Market Overview - On February 4, the medical services sector rose by 1.18% compared to the previous trading day, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 32.72, up 8.56%, with a trading volume of 144,400 shares and a transaction value of 464 million [1] - MediX (688202) closed at 63.84, up 3.70%, with a trading volume of 46,200 shares and a transaction value of 289 million [1] - Other notable performers include: - Purui Eye Hospital (301239) at 35.56, up 2.92% [1] - Tigermed (300347) at 64.94, up 2.75% [1] - Kanglong Chemical (300759) at 30.37, up 2.57% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 427 million from institutional investors, while retail investors experienced a net outflow of 439 million [2][3] - Notable net inflows from institutional investors include: - Tigermed (300347) with 158 million [3] - Aier Eye Hospital (300015) with 118 million [3] - WuXi AppTec (603259) with 112 million [3] Individual Stock Capital Flow - Tigermed (300347) had a net institutional inflow of 158 million, accounting for 14.54% of its trading volume [3] - Aier Eye Hospital (300015) had a net institutional inflow of 118 million, representing 12.46% of its trading volume [3] - Other stocks with significant institutional inflows include: - WuXi AppTec (603259) with 112 million [3] - Kanglong Chemical (300759) with 58.6 million [3]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]